Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -44.90% is 24% below its 5-year average of -36.23%, near the low end of its 5-year range (-59.43%–-3.20%).
19.46% below its 12-month average of -37.58%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.73%.
RETURN ON ASSETS (ROA)
-44.90%
RETURN ON ASSETS (ROA) AVG TTM
-37.58%
RETURN ON ASSETS (ROA) AVG 3Y
-38.70%
RETURN ON ASSETS (ROA) AVG 5Y
-36.23%
RETURN ON ASSETS (ROA) AVG 10Y
-56.01%
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-19.46%
CURRENT VS 3Y AVG
-16.04%
CURRENT VS 5Y AVG
-23.91%
CURRENT VS 10Y AVG
+19.84%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-31.81%
median of 841 covered companies
CURRENT VS SECTOR MEDIAN
-41.15%
vs the sector median at left
Ocular Therapeutix, Inc.
Market Cap
$1.62B
Return on Assets (ROA)
-44.90%
TTM Avg
-37.58%
3Y Avg
-38.70%
5Y Avg
-36.23%
Market Cap
$1.62B
Return on Assets (ROA)
7.08%
TTM Avg
2.00%
3Y Avg
-0.05%
5Y Avg
-1.77%
Market Cap
$1.62B
Return on Assets (ROA)
-4.28%
TTM Avg
-11.96%
3Y Avg
-5.19%
5Y Avg
-5.19%
Market Cap
$1.60B
Return on Assets (ROA)
1.96%
TTM Avg
0.34%
3Y Avg
0.01%
5Y Avg
0.90%
Market Cap
$1.60B
Return on Assets (ROA)
-43.15%
TTM Avg
-37.60%
3Y Avg
-124.49%
5Y Avg
-99.59%
Market Cap
$1.64B
Return on Assets (ROA)
-13.91%
TTM Avg
-19.51%
3Y Avg
-22.81%
5Y Avg
-24.34%
Market Cap
$1.54B
Return on Assets (ROA)
20.98%
TTM Avg
9.19%
3Y Avg
12.55%
5Y Avg
16.89%
Market Cap
$1.54B
Return on Assets (ROA)
-31.37%
TTM Avg
-48.93%
3Y Avg
-40.51%
5Y Avg
-30.14%
Market Cap
$1.54B
Return on Assets (ROA)
-52.77%
TTM Avg
-17.21%
3Y Avg
-29.94%
5Y Avg
-28.87%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Ocular Therapeutix, Inc. (OCUL) | $1.62B | -44.90% | -37.58% | -38.70% | -36.23% |
| ANI Pharmaceuticals, Inc. (ANIP)vs › | $1.62B | 7.08% | 2.00% | -0.05% | -1.77% |
| Septerna Inc (SEPN)vs › | $1.62B | -4.28% | -11.96% | -5.19% | -5.19% |
| Omnicell, Inc. (OMCL)vs › | $1.60B | 1.96% | 0.34% | 0.01% | 0.90% |
| Kestra Medical Technologies, Ltd. (KMTS)vs › | $1.60B | -43.15% | -37.60% | -124.49% | -99.59% |
| Alphatec Holdings, Inc. (ATEC)vs › | $1.64B | -13.91% | -19.51% | -22.81% | -24.34% |
| Innoviva, Inc. (INVA)vs › | $1.54B | 20.98% | 9.19% | 12.55% | 16.89% |
| Syndax Pharmaceuticals, Inc. (SNDX)vs › | $1.54B | -31.37% | -48.93% | -40.51% | -30.14% |
| Stoke Therapeutics, Inc. (STOK)vs › | $1.54B | -52.77% | -17.21% | -29.94% | -28.87% |
| uniQure N.V. (QURE)vs › | $1.54B | -25.60% | -33.58% | -30.56% | -19.71% |
ROA
-44.9%
ROE
-58.0%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -32.91% |
| 2024-12-31 | -42.26% |
| 2023-12-31 | -32.03% |
| 2022-12-31 | -47.58% |
| 2021-12-31 | -3.20% |
| 2020-12-31 | -59.43% |
| 2019-12-31 | -109.69% |
| 2018-12-31 | -78.98% |
| 2017-12-31 | -114.35% |
| 2016-12-31 | -59.65% |
| 2015-12-31 | -36.03% |
| 2014-12-31 | -36.64% |
| 2013-12-31 | -69.55% |
| 2012-12-31 | -55.74% |
